"Cell" finds a new type of cancer

In 2018, two pioneers in cancer immunotherapy won the Nobel Prize in Physiology or Medicine

The top academic journal "Cell" today published a new paper on cancer immunotherapy

The mechanism of cancer immunotherapy is easy to understand: our immune system can recognize viruses, bacteria and other pathogens, attack them, and keep us healthy

What immune cells are best suited to perform this function? The researchers focused their attention on a common type of white blood cell called polymorphonuclear neutrophils

As a member of the innate immune system, neutrophils can fight many different pathogens

In this research, scientists at the University of Chicago made a breakthrough

"Cells are constantly changing and mutations are constantly accumulating

How is this magical effect achieved? The researchers also answered in the paper

After CD95 is degraded, a protein fragment called the "death domain" is released, which plays an important role in the process of apoptosis

▲Schematic diagram of this research (picture source: reference [1])

It is precisely because the levels of histone H1 expressed by cancer cells and ordinary cells are different, scientists have found that ELANE can effectively kill a variety of different cancer cells without accidentally injuring the surrounding healthy cells

This is not over yet

Note: The original text has been deleted

Reference materials:

[1] Chang Cui et al.